New combo aims to outsmart Treatment-Resistant colorectal cancer

NCT ID NCT06634875

Recruiting now Disease control Sponsor: Buzzard Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Apr 03, 2026 · Last updated May 19, 2026 · Updated 6 times

Summary

This study tests a new drug, isunakinra, added to an existing immunotherapy (pembrolizumab) in 20 people with advanced colorectal cancer that has not responded to standard treatments. The cancer must have certain genetic features (MSS, TMB-H, KRAS mutation). The goal is to see if this combination can shrink tumors or slow their growth. Researchers will monitor safety and how long patients live without their cancer getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hoag Memorial Hospital Presbyterian
RECRUITING

Newport Beach, California, 92658, United States
USC/Norris Cancer Center
RECRUITING

Los Angeles, California, 90089, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

COLORECTAL CANCER METASTATIC